Phase IIa: Safety, PK, & Tolerability of Sodium Nitrite in Patients With Peripheral Arterial Disease-SONIC

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Peripheral Arterial Disease
Interventions
DRUG

sodium nitrite

0, 40 or 80 mg twice each day for 10 weeks followed by a 1 week escalation of 2 times the dose.

Trial Locations (10)

19104

University of Pennsylvania, Philadelphia

30322

Emory University, Atlanta

37232

Vanderbilt Heart and Vascular Institute, Nashville

43210

The Ohio State University, Columbus

44106

The Cleveland Clinic, Cleveland

University Hospitals, Cleveland

45267

University of Cincinnati, Cincinnati

52242

University of Iowa, Iowa City

53226

Medical College of Wisconsin, Milwaukee

80045

University of Colorado Denver Health Sciences Center, Aurora

All Listed Sponsors
lead

TheraVasc Inc.

INDUSTRY

NCT01401517 - Phase IIa: Safety, PK, & Tolerability of Sodium Nitrite in Patients With Peripheral Arterial Disease-SONIC | Biotech Hunter | Biotech Hunter